How Much Higher Can Recce Pharmaceuticals' (ASX: RCE) Share Price Go After the Recent Breakout?
Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.
Has Neuren Pharmaceuticals' (NEU) share price bottomed out?
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.
Immutep (ASX: IMM): A High-Risk Immunotherapy Bet Waiting for Phase III Validation
Immutep is a Sydney-based clinical-stage biotechnology company focused on immunotherapy, specifically targeting the LAG-3 immune pathway. The company is dual-listed on the ASX and NASDAQ, giving it access to both Australian and US capital markets. It does not yet generate commercial product revenue and remains dependent on capital markets and partnerships to fund its development programs, making it a milestone-driven investment rather than a revenue-backed operating business.
Has Telix Pharmaceutical's (ASX: TLX) share price reached the bottom?
Telix Pharmaceuticals is a radiopharmaceutical company focused on cancer imaging and therapies, with strong revenue growth driven by products like Illuccix and Gozellix. While recent gains suggest the stock may be stabilising, future performance will depend on continued commercial growth and pipeline progress.
Racura Oncology Ltd (ASX: RAC): Could RC220 Turn This Small Biotech into a Billion-Dollar Cancer Stock?
Racura Oncology is a clinical-stage biotech developing RC220 (bisantrene), a potential treatment for cancers such as AML and lung cancer. The company is pre-revenue and mainly funded through cash reserves and capital raises while advancing clinical trials. Its future valuation depends largely on trial results, regulatory progress and potential partnerships if the drug proves effective.
Massive Volume Surge in Botanix Pharmaceuticals (ASX: BOT): Is it finally finding a bottom?
Botanix Pharmaceuticals has seen a sharp volume spike after a major share price decline, hinting at possible bottoming. While Sofdra sales are growing and funding has improved liquidity, the stock remains in a downtrend, with any recovery dependent on stronger fundamentals and a break above key resistance.